Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImmix Biopharma Inc

Immix Biopharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
8.66 USD 0.31 ( 3.71%)
Last update at 2026-11-11T20:52:00Z
VOLUME
746265
Market Cap
868.49M

Momentum Score

…

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.30
Low
8.72
High
52 Week Price Range
1.98
Low
15.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Immix Biopharma Inc appears positioned as a clinical-stage biopharmaceutical company focused on oncology and immuno-oncology therapeutic development. Long-term growth may be driven by progression of clinical candidates, positive trial readouts and regulatory milestones, potential collaborations or licensing, and pipeline expansion. It may attract investors because successful clinical outcomes and partner deals could support meaningful upside relative to current market expectations.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.35
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-34.18%
Net Debt
-92.86M
ROCE
-31.62%
Diluted EPS TTM
-0.88

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -29.40M -21.66M -15.57M -8.22M -24.38M
Minority interest 0.00M 0.08M 0.17M - -
Net income -29.44M -21.61M -15.43M -8.23M -24.38M
Selling general administrative 13.70M 11.38M 7.41M 4.02M 1.23M
Selling and marketing expenses - - 0.01M - -
Gross profit -0.36M -0.12M -0.01M -89.52M -
Reconciled depreciation 0.36M 0.12M 0.00M 0.00M 0.00M
Ebit -29.96M -21.66M -15.57M -8.22M -1.35M
Ebitda -29.59M -21.54M -15.56M -8.22M -1.35M
Depreciation and amortization 0.36M 0.12M 0.01M 0.00M 0.00M
Operating income -29.96M -22.67M -16.14M -8.22M -1.35M
Other operating expenses 29.96M 22.67M 16.14M 8.22M 1.35M
Interest expense - - 0.00M 0.00M 0.18M
Tax provision 0.04M 0.04M 0.02M 0.01M 0.01M
Interest income 0.56M 1.02M 0.57M - -
Net interest income 0.56M 1.02M 0.34M -0.00M -0.18M
Income tax expense 0.04M 0.04M 0.03M 0.01M 0.01M
Total revenue 0.00M 0.00M 0.00M -89.52M 0.00M
Total operating expenses 29.96M 22.67M 16.14M 8.22M 1.35M
Cost of revenue 0.36M 0.12M 0.01M - -
Total other income expense net 0.56M 1.02M 0.57M -0.00M -23.03M
Net income from continuing ops -29.44M -21.70M -14.24M -8.23M -24.38M
Net income applicable to common shares - - - -8.23M -24.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 104.84M 22.95M 19.93M 14.91M 18.19M
Other current assets 0.83M 0.54M 1.11M 1.21M 0.52M
Total liab 11.04M 9.70M 3.72M 1.75M 0.20M
Total stockholder equity 93.80M 13.25M 16.41M 13.16M 17.99M
Other current liab 4.53M 3.23M 2.29M - 0.01M
Common stock 0.01M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.00M 0.00M 0.00M 0.00M
Retained earnings -104.46M -75.02M -53.41M -37.99M -29.76M
Other liab - - - 0.47M -
Other assets - - - 0.01M -
Cash 93.93M 17.68M 17.51M 13.44M 17.64M
Total current liabilities 10.11M 8.69M 3.72M 1.27M 0.20M
Net debt -92.86M -16.61M -17.51M -13.44M -17.59M
Short term debt 0.14M 0.07M - - 0.05M
Short long term debt - - - - 0.05M
Short long term debt total 1.07M 1.07M - - 0.05M
Other stockholder equity 198.19M 88.27M 69.68M 51.06M 47.62M
Property plant equipment - - - 0.00M 0.01M
Total current assets 101.24M 20.20M 19.79M 14.90M 18.19M
Net tangible assets - - - 13.16M 17.99M
Short term investments 6.48M 0.00M - - -
Net receivables - 1.97M 1.17M 0.26M 0.03M
Accounts payable 5.44M 5.39M 1.43M 1.27M 0.14M
Accumulated other comprehensive income 0.06M -0.00M 0.13M 0.09M 0.13M
Non currrent assets other 0.11M 0.02M 0.09M 0.01M 0.01M
Non current assets total 3.60M 2.75M 0.14M 0.01M 0.01M
Capital lease obligations 1.07M 1.07M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -6.48M -1.18M -0.04M 0.00M -0.00M
Change to liabilities - - - 1.13M -0.11M
Total cashflows from investing activities -7.21M -1.18M -0.05M - -0.00M
Net borrowings - - 0.00M -0.05M 0.20M
Total cash from financing activities 107.39M 15.95M 15.46M 3.23M 18.85M
Change to operating activities - - - -0.70M -0.38M
Net income -29.44M -21.70M -15.60M -8.23M -24.38M
Change in cash 76.25M 0.17M 4.07M -4.21M 17.25M
Begin period cash flow 17.68M 17.51M 13.44M 17.64M 0.39M
End period cash flow 93.93M 17.68M 17.51M 13.44M 17.64M
Total cash from operating activities -23.93M -14.60M -11.37M -7.41M -1.59M
Issuance of capital stock 107.39M 15.95M 15.11M 2.91M 18.65M
Depreciation 0.36M 0.12M 0.01M 0.00M 0.00M
Change to account receivables 2.06M -0.97M -0.89M - -
Sale purchase of stock - - -0.04M -0.10M -
Other cashflows from financing activities 107.39M 0.00M -0.23M 0.47M 0.20M
Change to netincome - - - 0.62M 23.12M
Capital expenditures 0.73M 1.18M 0.05M 0.00M 0.00M
Change in working capital 2.70M 3.97M 1.65M 0.20M -0.39M
Stock based compensation 2.44M 3.02M 2.57M 0.52M 0.22M
Other non cash items 2.70M 2.94M 2.26M 0.10M 0.12M
Free cash flow -24.66M -15.77M -11.42M -7.41M -1.59M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
IMMX
Immix Biopharma Inc		 0.31
3.71%		 8.66 - - - 3.82 -0.37
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Immix Biopharma Inc

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064

310 651 8041

https://www.immixbio.com

21

Name Title Year Born
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. Co-Founder, Chairman & CEO 1973
Mr. Gabriel Morris B.A. CFO & Director 1987
Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc Co-Founder NA
Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. Scientific Co-Founder 1947
Mr. Ben H. Lyon J.D. Exec. VP & Gen. Counsel NA
Dr. Graham Ross FFPM, M.D. Acting Chief Medical Officer & Head of Clinical Devel. 1960
Mr. Nandan Oza B.S. Head of Chemistry, Manufacturing & Control 1962
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. Co-Founder, CEO & Chairman 1973
Mr. Ben H. Lyon J.D. Executive VP & General Counsel NA
Dr. Graham Ross FFPM, M.D. Chief Medical Officer & Head of Clinical Development 1960

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…